- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01299558
Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects
9 juni 2017 uppdaterad av: GlaxoSmithKline
An Open-label, Non-randomised, Three-way Crossover, Single Dose Study to Determine the Absolute Bioavailability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder, in Healthy Subjects
This study is being done to look at the absolute bioavailability of fluticasone furoate and GW642444 inhalation powder when administered in healthy subjects.
Bioavailability is determined by measuring the amount of the dose of inhaled medication that reaches the circulation; the amount of inhaled fluticasone furoate and GW642444 powder will be compared to the medication administered intravenously (where bioavailability is 100%).
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Fluticasone furoate (FF), a novel glucocorticoid, and GW642444, a potent, inhaled longacting, beta2-receptor agonist (LABA), are currently under development in combination for use as a once-daily, inhaled treatment for asthma and chronic obstructive pulmonary disease (COPD).
FF is also being developed as a stand-alone product for asthma and GW642444 is also being developed as a stand-alone product and in combination with a novel, long-acting muscarinic antagonist for the treatment of COPD.
This study is being performed to determine the absolute bioavailability of both FF and GW642444 when delivered in combination from the novel dry powder inhaler.
Studietyp
Interventionell
Inskrivning (Faktisk)
16
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- GSK Investigational Site
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 64 år (Vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Healthy male or female between 18 and 64 years of age inclusive
- Body mass index (BMI) within the range 18.5-29 0 kg/m2 (inclusive)
- Subjects who are current non-smokers
- AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
- QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block, based on a single ECG value, or an average from three ECGs obtained over a brief recording period
- No significant abnormality on the Holter ECG at screening
- FEV1 ≥ 85% predicted at screening.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- Subjects who are able to use the inhalation device satisfactorily
Exclusion Criteria:
- As a result of medical interview, physical examination or screening investigations, the principal investigator or delegate physician deems the subject unsuitable for the study. Subjects must not have a systolic blood pressure above 145 mmHg or a diastolic pressure above 85 mmHg
- Any history of breathing problems in adult life
- Pregnant or lactating females
- The subject has been treated for or diagnosed with depression within six months of screening or has a history of significant psychiatric illness
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
- Subjects who have suffered a lower respiratory tract infection within 4 weeks of the screening visit
- Subjects with recent history (within 6 months) of pneumonia
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
- Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the new powder inhaler (i.e., lactose or magnesium stearate)
- History of milk protein allergy
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety
- The subject has taken oral corticosteroids less than 8 weeks before the screening visit
- The subject has taken inhaled, intranasal or topical steroids less than 4 weeks before the screening visit
- History of alcohol/drug abuse or dependence within 12 months of the study
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- The subject has tested positive for HIV antibodies
- A positive pre-study urine drug screen or when randomly tested during the study
- Positive carbon monoxide (CO) or alcohol breath test at screening or on admission to the Unit.
- Positive urine cotinine test at screening
- Consumption of seville oranges, pomelos (members of the grapefruit family) or grapefruit juice from 7 days prior to the first dose of study medication
- Unwillingness or inability to follow the procedures outlined in the protocol
- Subject is mentally or legally incapacitated
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: Treatment period 1
Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder given once daily in the morning on Day 1 of Treatment period 1
|
Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
|
Övrig: Treatment Period 2
Single IV dose of FF (250mcg) given over 20 mins on Day 1 of Treatment period 2
|
Single IV dose of FF (250mcg)
|
Övrig: Treatment Period 3
Single IV dose of GW642444M (55mcg) given over 60 mins on Day 1 of Treatment period 3
|
Single IV dose of GW642444 (55mcg)
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Absolute bioavailability of FF and GW642444 following single dose of FF/GW642444M Inhalation Powder; determined by measuring the amount of the dose of inhaled medication that reaches the circulation compared to the medication administered intravenously
Tidsram: Up to 48hr PK sampling periods profiles on 3 separate occasions over a total period of up to 5 weeks
|
Up to 48hr PK sampling periods profiles on 3 separate occasions over a total period of up to 5 weeks
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Pharmacokinetic parameters: AUC, Cmax, t1/2, tmax, and MRT for all treatments. In addition, volume of distribution (V) and plasma clearance (CL) for intravenous administrations and mean absorption time (MAT) for inhaled treatments
Tidsram: Up to 48hr PK sampling periods profiles on 3 separate occasions over a total period of up to 5 weeks
|
Up to 48hr PK sampling periods profiles on 3 separate occasions over a total period of up to 5 weeks
|
Number of Participants with clinically significant changes to Vital Signs as a measure of Safety and Tolerability
Tidsram: Approximately 9 weeks for each subject
|
Approximately 9 weeks for each subject
|
Number of Participants with clinically significant changes to 12-lead ECG Tests as a measure of Safety and Tolerability
Tidsram: Approximately 9 weeks for each subject
|
Approximately 9 weeks for each subject
|
Number of Participants with clinically significant changes to Clinical Laboratory Tests as a measure of Safety and Tolerability
Tidsram: Approximately 9 weeks for each subject
|
Approximately 9 weeks for each subject
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Tidsram: Approximately 9 weeks for each subject
|
Approximately 9 weeks for each subject
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
17 maj 2010
Primärt slutförande (Faktisk)
15 juli 2010
Avslutad studie (Faktisk)
15 juli 2010
Studieregistreringsdatum
Först inskickad
10 juni 2010
Först inskickad som uppfyllde QC-kriterierna
17 februari 2011
Första postat (Uppskatta)
18 februari 2011
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
12 juni 2017
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
9 juni 2017
Senast verifierad
1 juni 2017
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 102934
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Studiedata/dokument
-
Statistisk analysplan
Informationsidentifierare: 102934Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datauppsättning för individuella deltagare
Informationsidentifierare: 102934Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datauppsättningsspecifikation
Informationsidentifierare: 102934Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Annoterad fallrapportformulär
Informationsidentifierare: 102934Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Informerat samtycke
Informationsidentifierare: 102934Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisk studierapport
Informationsidentifierare: 102934Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokoll
Informationsidentifierare: 102934Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på fluticasone furoate//GW642444
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivFörenta staterna, Argentina, Estland, Kanada, Chile, Tyskland, Peru, Filippinerna, Mexiko, Korea, Republiken av, Danmark, Ryska Federationen, Polen, Slovakien
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivStorbritannien
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivSverige, Norge
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivJapan
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivJapan
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivSydafrika, Förenta staterna, Kanada, Ukraina, Storbritannien, Danmark, Tjeckien
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivStorbritannien
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivAustralien, Nya Zeeland
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivStorbritannien
-
GlaxoSmithKlineAvslutadLungsjukdom, kronisk obstruktivFörenta staterna, Argentina, Australien, Tyskland, Estland, Chile, Nederländerna, Peru, Sydafrika, Sverige, Mexiko, Storbritannien, Italien, Filippinerna, Kanada